David Hyman, MD

David Hyman, MD, Chief of Early Drug Development, Memorial Sloan Kettering Cancer Center, discusses efficacy results for larotrectinib (LOXO-101), a selective tropomyosin receptor kinase (TRK) inhibitor, in adult and pediatric TRK fusion cancers.

David Hyman, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the results of a phase I study of MEDI3617 for advanced solid tumors.